Article Text

PDF
▾ New topical β-blockers for glaucoma

Abstract

The introduction in 1979 of timolol eyedrops (Timoptol - MSD) was an important advance in the treatment of chronic open-angle glaucoma. Timolol’s relative lack of ocular unwanted effects,1 and its twice daily administration, makes it more acceptable than other eyedrops such as pilocarpine or adrenaline.2,3 But because it is absorbed through the nasal mucosa it can occasionally cause bradycardia and bronchospasm4 which may be fatal. It is also expensive. Carteolol (Teoptic) and betaxolol (Betoptic) are new ophthalmic β-blockers claimed to have a lower incidence of unwanted systemic effects. This is not claimed for metipranolol (Glauline) which is notably cheaper.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.